PHIL fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. Its products include Nidlegy, Fibromun, Darleukin, Dodekin, Onco IX, Tripokin, OncoFAP, and Dekavil. The company was founded by Dario Neri, Duccio Neri, and Giovanni Neri in 1996 and is headquartered in Siena, Italy.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
PHIL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company